383 related articles for article (PubMed ID: 23539390)
1. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
[TBL] [Abstract][Full Text] [Related]
2. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
3. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
4. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
[TBL] [Abstract][Full Text] [Related]
5. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.
Lordick F
Recent Results Cancer Res; 2012; 196():201-11. PubMed ID: 23129376
[TBL] [Abstract][Full Text] [Related]
6. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
[TBL] [Abstract][Full Text] [Related]
7. [
Harustiak T; Zemanova M; Fencl P; Hornofova L; Pazdro A; Snajdauf M; Salkova E; Lischke R; Stolz A
Br J Surg; 2018 Mar; 105(4):419-428. PubMed ID: 29417984
[TBL] [Abstract][Full Text] [Related]
8. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
9. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
[TBL] [Abstract][Full Text] [Related]
12. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
[TBL] [Abstract][Full Text] [Related]
13. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
14. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
[TBL] [Abstract][Full Text] [Related]
15. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
[TBL] [Abstract][Full Text] [Related]
16. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
17. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
18.
Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
[TBL] [Abstract][Full Text] [Related]
19. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
20. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
Ott K; Weber WA; Lordick F; Becker K; Busch R; Herrmann K; Wieder H; Fink U; Schwaiger M; Siewert JR
J Clin Oncol; 2006 Oct; 24(29):4692-8. PubMed ID: 16966684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]